Xeroderma Pigmentosum: Clinical Trials

1 trial for Xeroderma Pigmentosum, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 withdrawn. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Withdrawn 1

Follow Xeroderma Pigmentosum: new trials by email Literature Review of Xeroderma Pigmentosum trials Research Report on Xeroderma Pigmentosum

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Phase 1WithdrawnNational Cancer Institute (NCI)2021-05-112026-06-10

Narrower conditions

Central Nervous System Neoplasms (1)  ·  Colorectal Neoplasms, Hereditary Nonpolyposis (1)  ·  Hematologic Neoplasms (1)  ·  Lymphoma (1)  ·  Neuroblastoma (1)  ·  Turcot syndrome (1)

Broader conditions

Colonic Diseases (1)  ·  Colorectal Neoplasms (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  DNA Repair-Deficiency Disorders (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Genetic Diseases, Inborn (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Intestinal Diseases (1)

Interventions

CTLA-4 Antigen (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Specimen Handling (1)

Sponsors

National Cancer Institute (NCI) (1)

Countries

Canada (1)  ·  United States (1)

Top investigators

Daniel A Morgenstern (1)

NIH funding

P30CA015704 (1), UM1CA154967 (1)